Short-course R-CHOP followed by (90)Y-Ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients: 7-year long-term results

An update at 7 years was conceived for our multicenter phase II study in which 55 elderly high-risk untreated diffuse large B-cell lymphoma patients were treated with (90)Y-ibritumomab tiuxetan after a short course of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) as...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood Cancer J
Main Authors: Stefoni, V, Casadei, B, Bottelli, C, Gaidano, G, Ciochetto, C, Cabras, M G, Ansuinelli, M, Argnani, L, Broccoli, A, Gandolfi, L, Pellegrini, C, Zinzani, P L
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2016
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4916298/
https://ncbi.nlm.nih.gov/pubmed/27176801
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bcj.2016.29
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados